Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Intravesical chemotherapy
11 evidence topics · 9 sources
Guideline description: intravesical chemotherapy and chemotherapy combinations
Guideline description: device-assisted chemotherapy
Approval status: valrubicin approved, other intravesical chemotherapy used off-label
“Other intravesical chemotherapies commonly used off-label include gemcitabine, mitomycin C, and the doublet of gemcitabine and docetaxel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For over two decades, valrubicin was the only United States Food and Drug Administration (FDA) approved intravesical treatment for patients with BCG‐unresponsive carcinoma in situ (CIS) despite disease‐free rates of only 10% at 1 year following treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other options include non‐FDA approved therapies such as sequential intravesical gemcitabine and docetaxel” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“which is supported by retrospective evidence only and no prospective clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Valrubicin: labeled indication, dosing, and administration
Valrubicin: efficacy in BCG-refractory carcinoma in situ
Valrubicin: safety and the risk of delayed cystectomy
Sequential gemcitabine and docetaxel: multi-institution retrospective cohort after BCG
“Overall 276 patients (median age 73 years, median followup 22.9 months) received treatment. Nine patients were unable to tolerate a full induction course. One and 2-year recurrence-free survival rates were 60% and 46%, and high grade recurrence-free survival rates were 65% and 52%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-three patients (15.6%) went on to cystectomy (median 11.3 months from induction), of whom 11 (4.0%) had progression to muscle invasion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sequential gemcitabine and docetaxel: long-term single-institution follow-up after BCG failure
“Median follow-up was 49 months. Median age was 73 years, and 71% of the cohort had CIS containing disease. Thirty five percent of the cohort had BCG-unresponsive disease. Complete response at 3-month surveillance was 74% and median duration of response was 25 months. At 1, 2, and 5 years, HG-RFS was 60%, 50%, and 30%, respectively. HG-RFS was similar among BCG-unresponsive patients and the overall cohort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Five-year PFS, CFS, CSS, and OS were 82%, 75%, 91%, and 64%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sequential gemcitabine and docetaxel compared with additional BCG in BCG-unresponsive disease
“Of 299 total patients, 204 underwent additional BCG treatment at the time of BCG unresponsiveness and 95 underwent gem/doce treatment. Rates of PFS (HR 2.6, 95% confidence interval [CI] 1.1-5.0, p = 0.03), CFS (HR 2.0, 95% CI 1.2-3.4, p = 0.01), and CSS (HR 3.7, 95% CI 1.1-12.3, p=0.03) were higher in patients receiving gem/doce. HGRFS, MFS, and OS were similar between both groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sequential gemcitabine and docetaxel: prospective two-institution cohort in BCG-unresponsive disease
“Sixty-three patients were included. The median follow-up was 14 mo (interquartile range = 8-27). HGRFS rates at 3 and 12 mo were 88.8% (95% confidence interval [CI] = 81.3-97.0) and 68.1% (95% CI = 56.6-81.8), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eight patients (12.7%) underwent radical cystectomy and six patients (9.5%) experienced disease progression. Twenty patients (31.7%) experienced mild irritative symptoms and no grade 3 or 4 adverse events were reported.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Gemcitabine alone compared with sequential gemcitabine and docetaxel: regimens and outcomes
“Patients received 2 g of gemcitabine in 100 mL of saline, instilled into the bladder via a catheter for a minimum of 60 minutes once weekly for 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients received 1 g of gemcitabine in 50 mL of saline, instilled via catheter for 60 to 90 minutes. The bladder was then drained, and 37.5 mg of docetaxel in 50 mL of saline was instilled via a catheter for 60 to 120 minutes. This treatment sequence was administered weekly for 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median HGRFS was similar between groups (gemcitabine: 22.6 months; Gem/Doce: 19.5 months [P=.25]). Among patients with BCG-unresponsive carcinoma in situ (n=49), median HGRFS was comparable (gemcitabine: 12.2 months; Gem/Doce: 7.6 months [P=.12]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Low-grade adverse events were common (gemcitabine: 63%; Gem/Doce: 55% [P=.19]), but grade ≥3 adverse events were rare (2.3% vs 2.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sequential Gem/Doce also poses logistical barriers, including extended chair time, sequential instillation, staffing demands, and reimbursement issues, which may limit its adoption, especially in community settings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote